DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors.
The purpose of this study is to evaluate the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 overall response rate (ORR) in subsets of patients with advanced rare cancers treated with ipilimumab plus nivolumab combination immunotherapy.
- IRB Number: 1703616209 (S1609)
- Research Study Identifier: TX7674
- Principal Investigator: Kathy Miller, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required